Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial by Fakih, Marwan G, Prof, Kopetz, Scott, Prof, Kuboki, Yasutoshi, Prof, Kim, Tae Won, Prof, Munster, Pamela N, Prof, Krauss, John C, Prof, Falchook, Gerald S, Prof, Han, Sae-Won, Prof, Heinemann, Volker, Prof, Muro, Kei, Prof, Strickler, John H, Prof, Hong, David S, Prof, Denlinger, Crystal S, MD, Girotto, Gustavo, Prof, Lee, Myung-Ah, Prof, Henary, Haby, MD, Tran, Qui, PhD, Park, Joseph K, MD, Ngarmchamnanrith, Gataree, MD, Prenen, Hans, Prof, Price, Timothy J, Prof

Get full text

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial by Falchook, Gerald S, Dr, Long, Georgina V, PhD, Kurzrock, Razelle, Prof, Kim, Kevin B, MD, Arkenau, Tobias H, PhD, Brown, Michael P, PhD, Hamid, Omid, MD, Infante, Jeffrey R, MD, Millward, Michael, MD, Pavlick, Anna C, MD, O’Day, Steven J, MD, Blackman, Samuel C, PhD, Curtis, C Martin, BA, Lebowitz, Peter, PhD, Ma, Bo, PhD, Ouellet, Daniele, PhD, Kefford, Richard F, Prof

Get full text

MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study by Hong, David S, Prof, Hui, David, MD, Bruera, Eduardo, Prof, Janku, Filip, MD, Naing, Aung, MD, Falchook, Gerald S, MD, Piha-Paul, Sarina, MD, Wheler, Jennifer J, MD, Fu, Siqing, MD, Tsimberidou, Apostolia M, MD, Stecher, Michael, MD, Mohanty, Prasant, MBBS, Simard, John, BSc, Kurzrock, Razelle, Prof

Get full text

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial by Infante, Jeffrey R, Dr, Fecher, Leslie A, MD, Falchook, Gerald S, MD, Nallapareddy, Sujatha, MD, Gordon, Michael S, MD, Becerra, Carlos, MD, DeMarini, Douglas J, PhD, Cox, Donna S, PhD, Xu, Yanmei, MS, Morris, Shannon R, MD, Peddareddigari, Vijay GR, MD, Le, Ngocdiep T, MD, Hart, Lowell, MD, Bendell, Johanna C, MD, Eckhardt, Gail, MD, Kurzrock, Razelle, Prof, Flaherty, Keith, MD, Burris, Howard A, MD, Messersmith, Wells A, MD

Get full text

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial by Falchook, Gerald S, Dr, Lewis, Karl D, MD, Infante, Jeffrey R, MD, Gordon, Michael S, MD, Vogelzang, Nicholas J, MD, DeMarini, Douglas J, PhD, Sun, Peng, PhD, Moy, Christopher, MS, Szabo, Stephen A, BA, Roadcap, Lori T, MS, Peddareddigari, Vijay GR, MD, Lebowitz, Peter F, MD, Le, Ngocdiep T, MD, Burris, Howard A, MD, Messersmith, Wells A, MD, O'Dwyer, Peter J, Prof, Kim, Kevin B, MD, Flaherty, Keith, MD, Bendell, Johanna C, MD, Gonzalez, Rene, Prof, Kurzrock, Razelle, Prof, Fecher, Leslie A, MD

Get full text